Brandon Folkes
Stock Analyst at Rodman & Renshaw
(1.85)
# 2,976
Out of 4,784 analysts
47
Total ratings
27.45%
Success rate
-4.11%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMTI Rockwell Medical | Initiates: Buy | $5 | $1.14 | +338.60% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $2.78 | +331.65% | 1 | Nov 14, 2024 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $9 | $3.38 | +166.27% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $8.47 | +6.26% | 2 | Nov 14, 2024 | |
| ADIL Adial Pharmaceuticals | Initiates: Buy | $8 | $0.67 | +1,098.86% | 1 | Nov 14, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $16 | $4.66 | +243.35% | 6 | Sep 13, 2024 | |
| CRMD CorMedix | Initiates: Buy | $13 | $6.74 | +92.88% | 1 | Aug 26, 2024 | |
| MIST Milestone Pharmaceuticals | Initiates: Buy | $9 | $0.88 | +922.73% | 1 | Aug 22, 2024 | |
| MNKD MannKind | Initiates: Buy | $8 | $5.03 | +59.05% | 1 | Jun 13, 2024 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $7 | $6.50 | +7.69% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.26 | +209.73% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.36 | +635.29% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.24 | +5,243.20% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $30.19 | +95.43% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $122.92 | +46.44% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.51 | +4,229.86% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.11 | +47.30% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $33.21 | -3.64% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $2.79 | +788,430.47% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $29.71 | -25.95% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $720 | $2.74 | +26,177.37% | 1 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $67.61 | -40.84% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $9.15 | +3,342.62% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $27.65 | +80.83% | 1 | Jul 12, 2018 |
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.14
Upside: +338.60%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $2.78
Upside: +331.65%
Eupraxia Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.38
Upside: +166.27%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $8.47
Upside: +6.26%
Adial Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.67
Upside: +1,098.86%
Emergent BioSolutions
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $4.66
Upside: +243.35%
CorMedix
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $6.74
Upside: +92.88%
Milestone Pharmaceuticals
Aug 22, 2024
Initiates: Buy
Price Target: $9
Current: $0.88
Upside: +922.73%
MannKind
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $5.03
Upside: +59.05%
Trevi Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $6.50
Upside: +7.69%
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $2.26
Upside: +209.73%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $1.36
Upside: +635.29%
Jun 13, 2024
Initiates: Buy
Price Target: $13
Current: $0.24
Upside: +5,243.20%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $30.19
Upside: +95.43%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $122.92
Upside: +46.44%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.51
Upside: +4,229.86%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $6.11
Upside: +47.30%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $33.21
Upside: -3.64%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $2.79
Upside: +788,430.47%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $29.71
Upside: -25.95%
Jul 30, 2021
Initiates: Overweight
Price Target: $720
Current: $2.74
Upside: +26,177.37%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $67.61
Upside: -40.84%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $9.15
Upside: +3,342.62%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $27.65
Upside: +80.83%